Literature DB >> 1987036

PspA, a surface protein of Streptococcus pneumoniae, is capable of eliciting protection against pneumococci of more than one capsular type.

L S McDaniel1, J S Sheffield, P Delucchi, D E Briles.   

Abstract

Monoclonal antibodies against pneumococcal surface protein A (PspA) have been shown to protect mice from fatal pneumococcal infection. PspA is highly variable serologically, raising the possibility that PspA from one strain might not be able to elicit protective responses against strains which possess serologically different PspA. We have prepared a lambda gt11 library of pneumococcal genomic DNA and identified a clone expressing PspA. The recombinant PspA in this phage lysate elicited protection against pneumococcal infections with three strains of two different capsular serotypes. This finding demonstrated that PspA could elicit a protective response in the absence of other pneumococcal antigens. The observed protection was probably antibody mediated because it could be passively transferred with immune sera. Lambda lysates producing pneumococcal proteins other than PspA failed to elicit protection against fatal pneumococcal infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1987036      PMCID: PMC257730          DOI: 10.1128/iai.59.1.222-228.1991

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  22 in total

1.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

Authors:  J F Kearney; A Radbruch; B Liesegang; K Rajewsky
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

2.  Genetic control of the susceptibility to pneumococcal infection.

Authors:  D E Briles; J Horowitz; L S McDaniel; W H Benjamin; J L Claflin; C L Booker; G Scott; C Forman
Journal:  Curr Top Microbiol Immunol       Date:  1986       Impact factor: 4.291

3.  X-linked immune deficiency (xid) of CBA/N mice.

Authors:  L S Wicker; I Scher
Journal:  Curr Top Microbiol Immunol       Date:  1986       Impact factor: 4.291

4.  Antiidiotypic antibodies.

Authors:  D E Briles; J F Kearney
Journal:  Methods Enzymol       Date:  1985       Impact factor: 1.600

5.  Pneumococcal vaccine efficacy in selected populations in the United States.

Authors:  G Bolan; C V Broome; R R Facklam; B D Plikaytis; D W Fraser; W F Schlech
Journal:  Ann Intern Med       Date:  1986-01       Impact factor: 25.391

6.  Effect of immunization with pneumolysin on survival time of mice challenged with Streptococcus pneumoniae.

Authors:  J C Paton; R A Lock; D J Hansman
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

7.  Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae.

Authors:  D E Briles; M Nahm; K Schroer; J Davie; P Baker; J Kearney; R Barletta
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

8.  Epidemiological studies of Streptococcus pneumoniae in infants: development of antibody to phosphocholine.

Authors:  B M Gray; H C Dillon; D E Briles
Journal:  J Clin Microbiol       Date:  1983-11       Impact factor: 5.948

9.  Blood clearance by anti-phosphocholine antibodies as a mechanism of protection in experimental pneumococcal bacteremia.

Authors:  L S McDaniel; W H Benjamin; C Forman; D E Briles
Journal:  J Immunol       Date:  1984-12       Impact factor: 5.422

10.  Monoclonal antibodies against protease-sensitive pneumococcal antigens can protect mice from fatal infection with Streptococcus pneumoniae.

Authors:  L S McDaniel; G Scott; J F Kearney; D E Briles
Journal:  J Exp Med       Date:  1984-08-01       Impact factor: 14.307

View more
  80 in total

1.  The putative proteinase maturation protein A of Streptococcus pneumoniae is a conserved surface protein with potential to elicit protective immune responses.

Authors:  K Overweg; A Kerr; M Sluijter; M H Jackson; T J Mitchell; A P de Jong; R de Groot; P W Hermans
Journal:  Infect Immun       Date:  2000-07       Impact factor: 3.441

2.  Intranasal immunization of mice with a mixture of the pneumococcal proteins PsaA and PspA is highly protective against nasopharyngeal carriage of Streptococcus pneumoniae.

Authors:  D E Briles; E Ades; J C Paton; J S Sampson; G M Carlone; R C Huebner; A Virolainen; E Swiatlo; S K Hollingshead
Journal:  Infect Immun       Date:  2000-02       Impact factor: 3.441

3.  Pneumococcal 6-phosphogluconate-dehydrogenase, a putative adhesin, induces protective immune response in mice.

Authors:  D Daniely; M Portnoi; M Shagan; A Porgador; N Givon-Lavi; E Ling; R Dagan; Y Mizrachi Nebenzahl
Journal:  Clin Exp Immunol       Date:  2006-05       Impact factor: 4.330

4.  Analysis of serum cross-reactivity and cross-protection elicited by immunization with DNA vaccines against Streptococcus pneumoniae expressing PspA fragments from different clades.

Authors:  Eliane N Miyaji; Daniela M Ferreira; Alexandre P Y Lopes; M Cristina C Brandileone; Waldely O Dias; Luciana C C Leite
Journal:  Infect Immun       Date:  2002-09       Impact factor: 3.441

Review 5.  Pneumococcal and influenza vaccination: current situation and future prospects.

Authors:  F Horwood; J Macfarlane
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

6.  Genetic alteration of capsule type but not PspA type affects accessibility of surface-bound complement and surface antigens of Streptococcus pneumoniae.

Authors:  Melanie Abeyta; Gail G Hardy; Janet Yother
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

7.  Both family 1 and family 2 PspA proteins can inhibit complement deposition and confer virulence to a capsular serotype 3 strain of Streptococcus pneumoniae.

Authors:  Bing Ren; Alexander J Szalai; Orlanda Thomas; Susan K Hollingshead; David E Briles
Journal:  Infect Immun       Date:  2003-01       Impact factor: 3.441

8.  PspA protects Streptococcus pneumoniae from killing by apolactoferrin, and antibody to PspA enhances killing of pneumococci by apolactoferrin [corrected].

Authors:  Mirza Shaper; Susan K Hollingshead; William H Benjamin; David E Briles
Journal:  Infect Immun       Date:  2004-09       Impact factor: 3.441

9.  Immunization with Pneumococcal Surface Protein K of Nonencapsulated Streptococcus pneumoniae Provides Protection in a Mouse Model of Colonization.

Authors:  Lance E Keller; Xiao Luo; Justin A Thornton; Keun-Seok Seo; Bo Youn Moon; D Ashley Robinson; Larry S McDaniel
Journal:  Clin Vaccine Immunol       Date:  2015-08-26

10.  Protective humoral response against pneumococcal infection in mice elicited by recombinant bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A.

Authors:  S Langermann; S R Palaszynski; J E Burlein; S Koenig; M S Hanson; D E Briles; C K Stover
Journal:  J Exp Med       Date:  1994-12-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.